desipramine + lithium

Desipramine + lithium is a combination of two pharmaceutical agents used primarily in the management of major depressive disorder, particularly in cases resistant to standard antidepressant therapy. Desipramine is a tricyclic antidepressant (TCA) that acts mainly as a potent inhibitor of norepinephrine reuptake and, to a lesser extent, serotonin reuptake. Lithium is an elemental mood stabilizer commonly used in bipolar disorder and as an augmenting agent for treatment-resistant depression. The combination has been shown to induce greater antidepressant effects than either drug alone, both in preclinical models and clinical studies. Mechanistically, chronic co-administration may enhance hippocampal cell proliferation and neuroplasticity beyond what is observed with monotherapy[1][2][6]. This regimen is typically considered when patients do not respond adequately to tricyclic antidepressants alone.